Astaxanthin Effects on Osteoarthritis Associated Pain and Inflammatory Indicators
- Conditions
- Osteoarthritis, Knee
- Interventions
- Dietary Supplement: astaxanthinOther: Placebo
- Registration Number
- NCT03664466
- Lead Sponsor
- Saint Luke's Health System
- Brief Summary
This study is intended to assess the effects of astaxanthin use on pain, physical function, and inflammation as reflected by Patient-Reported Outcomes Measurement Information System (PROMIS) scores and levels of inflammatory biomarkers in subjects taking astaxanthin. If improvements in pain, function, and/or markers of inflammation could be demonstrated with the use of astaxanthin, this may suggest the potential for astaxanthin to be used in management of knee osteoarthritis (and possibly other forms of osteoarthritis) with less evident toxicity than seen with the presently available standard therapies (e.g. NSAIDS, opioids).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- All
- Target Recruitment
- Not specified
- Age 18 years or older
- Symptoms of knee pain
- Radiographic evidence of mild to moderate arthritis
- Able to provide written consent on their own behalf
- Pregnancy
- Current tobacco use
- Current substance abuse (alcohol or drug)
- Presence of significant cardiovascular, pulmonary, hepatic, or renal disease
- Prior history of knee trauma or surgery
- Gout or pseudogout
- Significant depression or anxiety scores on PHQ-9 and GAD-7, or pre-existing diagnosis of a significant mental health disorder
- Presence of other chronic pain syndromes such as chronic low back or neck pain, fibromyalgia, or complex regional pain syndrome
- Presence of systemic inflammatory conditions such as rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease
- Symptomatic involvement of multiple other joints with osteoarthritis
- Known allergy to fish or astaxanthin
- BMI greater than 35
- Participation in another clinical trial
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description Astaxanthin astaxanthin Astaxanthin 12mg twice daily by mouth Placebo Placebo Placebo twice daily by mouth
- Primary Outcome Measures
Name Time Method Change in PROMIS Numeric Rating Pain Scale 20 weeks Pain improvement in subjects is the primary outcome measure. The Patient Reported Outcomes Measurement Information Systems (PROMIS) Pain Intensity Scale 1a tool will be used. This scale ranges from 0-10, with 0 representing no pain and 10 representing the worst pain imaginable.
- Secondary Outcome Measures
Name Time Method Change in PROMIS Physical function score 20 weeks Improvement in physical function is a secondary outcome measure. The PROMIS Physical Function Short Form 6b will be used as the survey tool for physical limitation. There are 5 levels of limitation to physical function from 0 (without any difficulty) to 5 (unable to do). The higher the score, the greater the limitation
Change in C-reactive protein levels 20 weeks Change in CRP levels (mg/L)
Change in Cartilage Oligomeric Matrix Protein levels 20 weeks Change in COMP levels (ng/mL)
Change in PROMIS Pain interference score 20 weeks Reduction in pain interference is a secondary outcome measure. The Patient Reported Outcomes Measurement Information Systems (PROMIS) Pain Interference Short Form 6b will be used as the survey tool for pain interference. This is a set of 6 questions to assess the degree to which pain has interfered with daily activities. There are 5 levels of pain interference from 0 (none at all) to 5 (very much or always). The higher the score, the greater the pain interference.
Change in Erythrocyte Sedimentation Rate 20 weeks Change in ESR (mm/hr)
Change in Interleukin-6 levels 20 weeks Change in IL-6 levels (pg/mL)
Trial Locations
- Locations (1)
Saint Luke's Hospital of Kansas City
🇺🇸Kansas City, Missouri, United States